This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
April 19, 2018
MIPS and POC Sweden have reached a settlement and will strengthen their cooperation
April 16, 2018
Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 American Association of Cancer Research (AACR) Annual Meeting in Chicago
April 16, 2018
Nordic Nanovector Presents Preclinical Data at AACR 2018
April 12, 2018
Targovax strengthens Board of Directors with the appointment of Catherine Wheeler
April 12, 2018
First patient starts treatment in Oncopeptides’ Phase I / II ANCHOR study with Ygalo®
April 12, 2018
Promising preliminary long-term data for WTX101 in Wilson Disease presented at EASL Annual Meeting
April 11, 2018
Statement by the Independent Committee of the Board of Directors of Wilson Therapeutics in relation to the public offer from Alexion
April 04, 2018
Nordic Nanovector provides update on the PARADIGME clinical trial
April 04, 2018
Nordic Nanovector announces that Luigi Costa will step down as Chief Executive Officer
April 03, 2018
GenSight Biologics announces topline results from REVERSE Phase III clinical trial of GS010 in patients with Leber Hereditary Optic Neuropathy (LHON)